- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Supriya Lifescience reported strong Q3 FY26 results: Revenue grew 11.2% YoY to Rs 206.44 Cr, with PAT at Rs 49.68 Cr. Anesthetic and vitamin segments drove growth as capacity utilization improved to 76%. The Ambernath formulation facility launch is set for Q4 FY26.